JP6550053B2 - 腫瘍を治療するための抗ｂ７−ｈ１抗体 - Google Patents

腫瘍を治療するための抗ｂ７−ｈ１抗体 Download PDF

Info

Publication number
JP6550053B2
JP6550053B2 JP2016542315A JP2016542315A JP6550053B2 JP 6550053 B2 JP6550053 B2 JP 6550053B2 JP 2016542315 A JP2016542315 A JP 2016542315A JP 2016542315 A JP2016542315 A JP 2016542315A JP 6550053 B2 JP6550053 B2 JP 6550053B2
Authority
JP
Japan
Prior art keywords
medi
tumor
binding fragment
patient
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016542315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530323A5 (enExample
JP2016530323A (ja
Inventor
ナーワル，ラジェッシュ
フェアマン，デーヴィッド
ロビンズ，ポール
リャン，メイナ
シュナイダー，エイミー
チャベス，カルロス
ハール，カリーナ
パク，ミン
ル，ホン
レベラット，マーロン
スティール，ケイス
ボウトリン，アンマリー
シ，リ
ホン，シェンヤン
ヒッグズ，ブランドン
ロスコス，ローリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2016530323A publication Critical patent/JP2016530323A/ja
Publication of JP2016530323A5 publication Critical patent/JP2016530323A5/ja
Application granted granted Critical
Publication of JP6550053B2 publication Critical patent/JP6550053B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016542315A 2013-09-11 2014-09-11 腫瘍を治療するための抗ｂ７−ｈ１抗体 Active JP6550053B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361876509P 2013-09-11 2013-09-11
US61/876,509 2013-09-11
US201461971212P 2014-03-27 2014-03-27
US61/971,212 2014-03-27
US201461978401P 2014-04-11 2014-04-11
US61/978,401 2014-04-11
US201462003349P 2014-05-27 2014-05-27
US62/003,349 2014-05-27
PCT/EP2014/069425 WO2015036499A1 (en) 2013-09-11 2014-09-11 Anti-b7-h1 antibodies for treating tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019081639A Division JP2019163269A (ja) 2013-09-11 2019-04-23 腫瘍を治療するための抗ｂ７−ｈ１抗体

Publications (3)

Publication Number Publication Date
JP2016530323A JP2016530323A (ja) 2016-09-29
JP2016530323A5 JP2016530323A5 (enExample) 2017-10-12
JP6550053B2 true JP6550053B2 (ja) 2019-07-24

Family

ID=51570487

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016542315A Active JP6550053B2 (ja) 2013-09-11 2014-09-11 腫瘍を治療するための抗ｂ７−ｈ１抗体
JP2019081639A Pending JP2019163269A (ja) 2013-09-11 2019-04-23 腫瘍を治療するための抗ｂ７−ｈ１抗体
JP2020152079A Active JP7119037B2 (ja) 2013-09-11 2020-09-10 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2022021883A Active JP7342167B2 (ja) 2013-09-11 2022-02-16 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2023139429A Pending JP2023166474A (ja) 2013-09-11 2023-08-30 腫瘍を治療するための抗ｂ７－ｈ１抗体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019081639A Pending JP2019163269A (ja) 2013-09-11 2019-04-23 腫瘍を治療するための抗ｂ７−ｈ１抗体
JP2020152079A Active JP7119037B2 (ja) 2013-09-11 2020-09-10 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2022021883A Active JP7342167B2 (ja) 2013-09-11 2022-02-16 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2023139429A Pending JP2023166474A (ja) 2013-09-11 2023-08-30 腫瘍を治療するための抗ｂ７－ｈ１抗体

Country Status (19)

Country Link
US (3) US10336823B2 (enExample)
EP (2) EP3043816B1 (enExample)
JP (5) JP6550053B2 (enExample)
KR (4) KR20240056664A (enExample)
CN (2) CN105873606B (enExample)
AU (3) AU2014320343B2 (enExample)
BR (1) BR112016005303A2 (enExample)
CA (1) CA2923499A1 (enExample)
DK (1) DK3043816T3 (enExample)
ES (1) ES2749744T3 (enExample)
HU (1) HUE046674T2 (enExample)
IL (5) IL313188B1 (enExample)
MX (1) MX370818B (enExample)
NZ (2) NZ757060A (enExample)
PL (1) PL3043816T3 (enExample)
RU (1) RU2701327C2 (enExample)
SA (1) SA516370713B1 (enExample)
TW (1) TWI643633B (enExample)
WO (1) WO2015036499A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
IL313188B1 (en) * 2013-09-11 2025-08-01 Medimmune Ltd Anti-B7-H1 antibodies for tumor treatment
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
WO2015181342A1 (en) 2014-05-29 2015-12-03 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
CN106456764A (zh) * 2014-05-29 2017-02-22 免疫医疗有限公司 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
EP3189080A1 (en) * 2014-09-05 2017-07-12 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN107530434A (zh) * 2015-04-23 2018-01-02 免疫医疗有限公司 非小细胞肺癌egfr突变阳性的联合疗法
CN107667119A (zh) * 2015-05-12 2018-02-06 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. NOVEL ANTI-PD-L1 ANTIBODIES
MX390878B (es) 2015-06-16 2025-03-21 Merck Patent Gmbh Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
EP3464356A1 (en) * 2016-05-26 2019-04-10 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for cancer treatment
NZ789594A (en) 2016-06-20 2025-07-25 Kymab Ltd Anti-PD-L1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018003995A1 (ja) * 2016-07-01 2018-01-04 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
CN111372934B (zh) 2017-08-18 2024-04-26 科瑞华生物技术有限公司 Tg02的多晶型形式
WO2019152743A1 (en) * 2018-01-31 2019-08-08 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
CN119899267A (zh) * 2018-03-22 2025-04-29 赛因格先进生物技术弗朗哥塞尔瓦托有限责任公司 拮抗性pd-1、pd-l1和lag-3结合蛋白
CN113438947A (zh) 2019-01-18 2021-09-24 羿尊生物医药股份有限公司 Don前药和免疫检查点抑制剂的联合治疗
WO2020151759A1 (zh) * 2019-01-25 2020-07-30 正大天晴药业集团股份有限公司 治疗肿瘤的联用药物组合物
MX2021011753A (es) 2019-03-26 2022-01-31 Univ Michigan Regents Degradadores de moleculas peque?as de stat3.
EP3947403A1 (en) 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
AU2020291936A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
AU2020291464A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
AU2020301417A1 (en) * 2019-06-25 2022-01-06 City Of Hope PDL1 positive NK cell cancer treatment
CN115443329A (zh) 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
PH12021553233A1 (en) 2019-07-16 2022-09-19 Univ Michigan Regents Imidazopyrimidines as eed inhibitors and the use thereof
CN114641337A (zh) 2019-08-27 2022-06-17 密歇根大学董事会 Cereblon e3连接酶抑制剂
EP4031241A1 (en) 2019-09-19 2022-07-27 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
JP7445752B2 (ja) * 2019-09-25 2024-03-07 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－ｌ１抗体
US20230159573A1 (en) 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
WO2022072820A1 (en) 2020-10-02 2022-04-07 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
WO2022187419A1 (en) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
WO2022200557A1 (en) * 2021-03-26 2022-09-29 Astrazeneca Ab Combination treatments for melanoma
TW202444754A (zh) 2023-01-30 2024-11-16 英商凱麥博有限公司 抗體
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
WO2002086083A2 (en) * 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US20100285039A1 (en) * 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN101693562A (zh) * 2009-10-21 2010-04-14 山东大学 一种聚合氯化铁-聚环氧氯丙烷-二甲胺复合混凝剂
DK2504364T3 (da) * 2009-11-24 2017-11-06 Medimmune Ltd Målrettede bindemidler mod b7-h1
SMT202000561T1 (it) * 2011-11-28 2021-01-05 Merck Patent Gmbh Anticorpi anti-pd-l1 e usi relativi
SG10201700698WA (en) * 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
IL313188B1 (en) 2013-09-11 2025-08-01 Medimmune Ltd Anti-B7-H1 antibodies for tumor treatment
MX373019B (es) * 2014-05-13 2020-03-31 Medimmune Ltd Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antígeno 4 de linfocito t citotóxico (anti-ctla-4).
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3189080A1 (en) * 2014-09-05 2017-07-12 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)
EP3220951A1 (en) * 2014-11-17 2017-09-27 MedImmune Limited Therapeutic combinations and methods for treating neoplasia
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
SG11201807474SA (en) * 2016-04-25 2018-11-29 Medimmune Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
AU2017264944A1 (en) * 2016-05-13 2018-12-20 Medimmune, Llc CD40L-Fc fusion polypeptides and methods of use thereof

Also Published As

Publication number Publication date
KR20240056664A (ko) 2024-04-30
RU2701327C2 (ru) 2019-09-25
IL292193A (en) 2022-06-01
EP3043816A1 (en) 2016-07-20
RU2019128452A (ru) 2019-10-24
AU2014320343B2 (en) 2020-05-28
IL292193B2 (en) 2024-11-01
JP2023166474A (ja) 2023-11-21
JP2022065100A (ja) 2022-04-26
SA516370713B1 (ar) 2019-03-10
US20160222120A1 (en) 2016-08-04
AU2014320343A1 (en) 2016-04-21
IL321966A (en) 2025-09-01
JP7119037B2 (ja) 2022-08-16
AU2020223728A1 (en) 2020-09-17
IL313188A (en) 2024-07-01
JP2021006537A (ja) 2021-01-21
CN105873606A (zh) 2016-08-17
WO2015036499A1 (en) 2015-03-19
CN112546217B (zh) 2025-04-29
MX370818B (es) 2020-01-08
US10336823B2 (en) 2019-07-02
KR20210143932A (ko) 2021-11-29
KR102329584B1 (ko) 2021-11-22
IL274462A (en) 2020-06-30
KR20160044030A (ko) 2016-04-22
JP2019163269A (ja) 2019-09-26
KR102661249B1 (ko) 2024-04-25
TWI643633B (zh) 2018-12-11
JP2016530323A (ja) 2016-09-29
EP3043816B1 (en) 2019-08-14
US20190338033A1 (en) 2019-11-07
US20210171639A1 (en) 2021-06-10
NZ718821A (en) 2022-07-01
IL313188B1 (en) 2025-08-01
EP3656398A1 (en) 2020-05-27
AU2024203898A1 (en) 2024-07-04
JP7342167B2 (ja) 2023-09-11
US10829557B2 (en) 2020-11-10
AU2020223728B2 (en) 2024-03-07
TW201605472A (zh) 2016-02-16
IL274462B (en) 2022-05-01
KR20220162843A (ko) 2022-12-08
IL244422A0 (en) 2016-04-21
RU2016113341A3 (enExample) 2018-05-30
RU2016113341A (ru) 2017-10-16
BR112016005303A2 (pt) 2017-09-12
IL244422B (en) 2020-05-31
MX2016002826A (es) 2016-09-13
HUE046674T2 (hu) 2020-03-30
PL3043816T3 (pl) 2020-03-31
ES2749744T3 (es) 2020-03-23
CN112546217A (zh) 2021-03-26
IL292193B1 (en) 2024-07-01
US11827706B2 (en) 2023-11-28
DK3043816T3 (da) 2019-10-14
CN105873606B (zh) 2020-12-29
CA2923499A1 (en) 2015-03-19
NZ757060A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
JP7342167B2 (ja) 腫瘍を治療するための抗ｂ７－ｈ１抗体
JP2017517525A (ja) Ｈｐｖ陰性がんの治療のためのｐｄｌ−１およびｐｄ−１のアンタゴニスト
US20240150469A1 (en) Anti-b7-h1 antibodies for treating tumors
HK40030575A (en) Anti-b7-h1 antibodies for treating tumors
RU2817281C2 (ru) Антитела к b7-h1 для лечения опухолей
HK1224560B (zh) 用於治疗肿瘤的抗b7-h1抗体
HK1226964B (en) Anti-b7-h1 antibodies for treating tumors
HK1226964A1 (en) Anti-b7-h1 antibodies for treating tumors
HK1224560A1 (en) Anti-b7-h1 antibodies for treating tumors

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190628

R150 Certificate of patent or registration of utility model

Ref document number: 6550053

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250